EP1180999A4 - Recombinant vaccine against botulinum neurotoxin - Google Patents

Recombinant vaccine against botulinum neurotoxin

Info

Publication number
EP1180999A4
EP1180999A4 EP00932296A EP00932296A EP1180999A4 EP 1180999 A4 EP1180999 A4 EP 1180999A4 EP 00932296 A EP00932296 A EP 00932296A EP 00932296 A EP00932296 A EP 00932296A EP 1180999 A4 EP1180999 A4 EP 1180999A4
Authority
EP
European Patent Office
Prior art keywords
vaccine against
botulinum neurotoxin
recombinant vaccine
against botulinum
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00932296A
Other languages
German (de)
French (fr)
Other versions
EP1180999A2 (en
Inventor
Leonard A Smith
Michael P Byrne
John L Middlebrook
Hugh Lapenotiere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Army Medical Research and Materiel Command USAMRMC
Original Assignee
US Army Medical Research and Materiel Command USAMRMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Army Medical Research and Materiel Command USAMRMC filed Critical US Army Medical Research and Materiel Command USAMRMC
Publication of EP1180999A2 publication Critical patent/EP1180999A2/en
Publication of EP1180999A4 publication Critical patent/EP1180999A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00932296A 1999-05-12 2000-05-12 Recombinant vaccine against botulinum neurotoxin Ceased EP1180999A4 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US13386699P 1999-05-12 1999-05-12
US13386999P 1999-05-12 1999-05-12
US13386799P 1999-05-12 1999-05-12
US13387399P 1999-05-12 1999-05-12
US13386599P 1999-05-12 1999-05-12
US13386899P 1999-05-12 1999-05-12
US133869P 1999-05-12
US133868P 1999-05-12
US133866P 1999-05-12
US133867P 1999-05-12
US133873P 1999-05-12
US133865P 1999-05-12
US14619299P 1999-07-29 1999-07-29
US146192P 1999-07-29
PCT/US2000/012890 WO2000067700A2 (en) 1999-05-12 2000-05-12 Recombinant vaccine against botulinum neurotoxin

Publications (2)

Publication Number Publication Date
EP1180999A2 EP1180999A2 (en) 2002-02-27
EP1180999A4 true EP1180999A4 (en) 2005-03-30

Family

ID=27568892

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00932296A Ceased EP1180999A4 (en) 1999-05-12 2000-05-12 Recombinant vaccine against botulinum neurotoxin

Country Status (5)

Country Link
EP (1) EP1180999A4 (en)
JP (1) JP2004512004A (en)
AU (1) AU783450B2 (en)
CA (1) CA2371279A1 (en)
WO (1) WO2000067700A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
WO2003012117A1 (en) * 2001-07-28 2003-02-13 The Secretary Of State For Defence Dna vaccine
WO2006011966A1 (en) 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
CA2575994A1 (en) * 2004-08-04 2006-02-16 Allergan, Inc. Optimizing expression of active botulinum toxin type a
FR2889066B1 (en) * 2005-07-28 2007-11-09 Centre Nat Rech Scient METHOD OF GENETIC IMMUNIZATION BY ELECTROTRANSFER AGAINST TOXIN AND ANTISERUM THAT CAN BE OBTAINED BY THIS PROCESS
JP2009106163A (en) * 2007-10-26 2009-05-21 Kyushu Univ Nucleic acid sequence, vector, transformant, production method, and nucleic acid sequence primer
AU2010309932B2 (en) 2009-10-21 2015-04-16 Merz Pharma Gmbh & Co. Kgaa System for determining unprocessed and partially processed neurotoxin type A
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
EP3822286A1 (en) 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Cationic neurotoxins
JP6910961B2 (en) * 2015-05-15 2021-07-28 ヌーテック ベンチャーズ Genetically engineered Clostridium botulinum toxin for molecular delivery to selected cells
WO2019126502A1 (en) * 2017-12-20 2019-06-27 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation
CN110075288B (en) * 2019-05-06 2022-04-26 中国兽医药品监察所 Nontoxic C-type clostridium botulinum genetic engineering subunit vaccine and production method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9511909D0 (en) * 1995-06-12 1995-08-09 Microbiological Res Authority Vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BYRNE MICHAEL P ET AL: "Purification, potency, and efficacy of the botulinum neurotoxin type A biding domain from Pichia pastoris as a recombinant vaccine candidate", INFECTION AND IMMUNITY, vol. 66, no. 10, October 1998 (1998-10-01), pages 4817 - 4822, XP002301389, ISSN: 0019-9567 *
CLAYTON M A ET AL: "Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in E. coli", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 63, no. 7, July 1995 (1995-07-01), pages 2738 - 2742, XP002110803, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
AU783450B2 (en) 2005-10-27
CA2371279A1 (en) 2000-11-16
WO2000067700A2 (en) 2000-11-16
JP2004512004A (en) 2004-04-22
AU5003500A (en) 2000-11-21
EP1180999A2 (en) 2002-02-27
WO2000067700A3 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
IL146974A0 (en) Therapeutic composition comprising a botulinum neurotoxin
MXPA02010787A (en) Modified peptides as therapeutic agents.
ZA991662B (en) Recombinant and adjuvant-containing live vaccines.
ZA200308589B (en) Recombinant fusion proteins and the trimers thereof.
EP1180999A4 (en) Recombinant vaccine against botulinum neurotoxin
EP1083883A4 (en) Stabilizers for lyophilized vaccines
EP1105153A4 (en) Multivalent vaccine for (clostridium botulinum) neurotoxin
HUP0202650A3 (en) Fibrinolytically active polypeptide
GB9923177D0 (en) Novel polypeptide
EP1204424A4 (en) Recombinant rsv virus expression systems and vaccines
EP1244780A4 (en) Dna encoding the human serine protease t
AUPQ233799A0 (en) Recombinant sub-unit vaccine
EP1246635A4 (en) O-superfamily conotoxin peptides
EP1094071A4 (en) Novel peptide y-2
EP1189632A4 (en) Pneumococcal surface protein combination vaccine
GB9914861D0 (en) Tetanus toxin polypeptides
EP1162269A4 (en) Novel polypeptide
AU2232399A (en) Recombinant ctb-based vaccines
EP1179540A4 (en) Novel polypeptide
IL145233A0 (en) Recombinant plant proteins and methods utilizing the same
EP1458736A4 (en) Recombinant bovine thrombin
HK1045173A1 (en) Polypeptide
SI1185291T1 (en) Therapeutic agent comprising a botulinum neurotoxin
GB9921275D0 (en) Recombinant microorganisms
GB9923888D0 (en) Novel polypeptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011211

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/11 A, 7C 12N 15/63 B, 7C 07H 21/04 B, 7C 07K 5/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20050210

17Q First examination report despatched

Effective date: 20071109

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20150716